Last reviewed · How we verify

Silodosin Capsules

Xintian Pharmaceutical · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Silodosin Capsules is a Small molecule drug developed by Xintian Pharmaceutical. It is currently FDA-approved. Also known as: Qianweitai.

Silodosin capsules are used to treat conditions such as Benign Prostatic Hyperplasia and Prostatic Hyperplasia. Silodosin is a medication that works by relaxing the muscles in the prostate and bladder neck, as indicated by its classification in ChEMBL as an alpha-1 adrenergic receptor antagonist.

At a glance

Generic nameSilodosin Capsules
Also known asQianweitai
SponsorXintian Pharmaceutical
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Silodosin Capsules

What is Silodosin Capsules?

Silodosin Capsules is a Small molecule drug developed by Xintian Pharmaceutical.

Who makes Silodosin Capsules?

Silodosin Capsules is developed and marketed by Xintian Pharmaceutical (see full Xintian Pharmaceutical pipeline at /company/xintian-pharmaceutical).

Is Silodosin Capsules also known as anything else?

Silodosin Capsules is also known as Qianweitai.

What development phase is Silodosin Capsules in?

Silodosin Capsules is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing